Invivyd, Inc.
Close on Oct 19, 2026
- Market cap
- $195.47M
- P/E (TTM)
- –
- Dividend yield
- –
About Invivyd
Biological Products, (No Diagnostic Substances), SIC 2836
Invivyd, Inc. is a biopharmaceutical company that discovers, develops, and commercializes monoclonal antibody therapies to prevent and treat serious viral infectious diseases. Its primary product is PEMGARDA, an authorized monoclonal antibody used as pre-exposure prophylaxis against COVID-19. The company also develops investigational candidates, including VYD2311 for COVID-19 and VBY329 for respiratory syncytial virus, alongside early research targeting measles. Its treatments serve vulnerable populations, specifically immunocompromised adults and adolescents who cannot generate an adequate immune response from vaccination, distributed through specialized healthcare practitioners in oncology, hematology, rheumatology, and transplantation.
The company conducts commercial activities and maintains a field sales force in the United States. Its clinical evaluations include trials conducted in Australia, alongside global studies for foundational antibody programs. Invivyd operates dedicated laboratory space and relies on external contract research organizations as well as WuXi Biologics in Hong Kong for development, manufacturing, and product supply. The provided text does not state the location of the company's headquarters.
Summary of the business section of Invivyd's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Invivyd, Inc.
- Headquarters
- New Haven, CT
- Address
- 205 Church Street
- Phone
- (781) 819-0080
- Website
- invivyd.com
- Employees
- 122, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- IVVD
- Exchange
- Nasdaq
- IPO date
- Aug 6, 2021
- Shares outstanding
- 295M, Jul 30, 2026
- Public float
- $50.90M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1832038
- CUSIP
- 00534A102
- ISIN
- US00534A1025
- EIN
- 85-1403134
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Marc Elia | Chief Executive Officer, Director | 9,248,250 |
| William E. Duke | Chief Financial Officer | 168,937 |
| Robert D. Allen III | Chief Scientific Officer | 178,765 |
| Jill Andersen | Chief Legal Officer, Secretary | 284,274 |
| Timothy Edward Lee | Chief Commercial Officer | 178,937 |
| Julie Green | Chief Human Resources Officer | 168,937 |
| Michael Mina | CMO and Chief Epidemiologist | – |
| Ian Sheffield | Director | – |
| Terrance McGuire | Director | 3,066,757 |
| Kevin F. McLaughlin | Director | 50,000 |
| Paul Bolno | Director | – |
| Ajay Royan | Director | 11,241,580 |
| Tamsin Berry | Director | – |
| Christine Lindenboom | Director | – |
Employees
Headcount reported in annual reports
“As of February 1, 2026, we had 122 employees, all of which were full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 24, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 25, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Dec 27, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 12, 2022 | Name change | Name changed from Adagio Therapeutics, Inc. to Invivyd, Inc. |
| Aug 6, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 3, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |